Search Press releases Keywords From To 26 Mar 2026 UCB receives positive CHMP opinion for new ZILBRYSQ[®]▼ (zilucoplan) pre-filled pen in EU for adults living with generalized myasthenia gravis Read More 24 Mar 2026 UCB Selects Georgia for New U.S. Biologics Manufacturing Facility; ~$5B Economic Impact and ~330 Permanent Jobs Read More 20 Mar 2026 Acquisition of own shares Read More 13 Mar 2026 Share Repurchase Program 2026 to cover UCB's Long Term Incentive Plans for employees Read More 11 Mar 2026 BIMZELX[®]▼(bimekizumab) superior to SKYRIZI[®] (risankizumab) in BE BOLD: first head-to-head study in active psoriatic arthritis (PsA) to demonstrate superiority in ACR50 Read More 3 Mar 2026 UCB and Antengene enter global license agreement for ATG-201, a B cell-depleting bispecific antibody Read More Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Page 1 of 61 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe